BioCentury
ARTICLE | Clinical News

Meritas Troponin I test regulatory update

February 17, 2014 8:00 AM UTC

Trinity said its Meritas Troponin I point-of-care test received CE Mark approval as an aid in diagnosing myocardial infarction (MI) in the emergency room. The company immediately launched the fluorescence immunoassay for in vitro quantitative determination of troponin I from whole blood and plasma specimens in Europe. Trinity gained the assay through its 2012 acquisition of Fiomi Diagnostics AB (see BioCentury, March 12, 2012). ...